Roivant Sciences (ROIV) Jefferies Global Healthcare Conference 2026 summary

Recent performance and strategic focus

• Achieved significant progress with three late-stage drugs: brepocitinib, IMVT-1402, and mosliciguat, with a major commercial launch for brepocitinib in dermatomyositis expected by end of September, pending FDA approval.

• Emphasizes creative, aggressive clinical development and disciplined capital allocation, maintaining a focus on both internal pipeline execution and ongoing business development opportunities.

• Current pipeline considered sufficient for near-term growth, with a focus on execution rather than immediate asset acquisition.

Commercial launch and market strategy for dermatomyositis (DM)

• Brepocitinib is positioned as the first modern targeted therapy to succeed in phase III for DM, with strong physician and patient community anticipation.

• Commercial strategy draws on lessons from other rare disease launches, focusing on pricing, rebating, organizational structure, and patient support.

• Pricing expected to be at the lower end of a $200,000–$600,000 range, prioritizing access and broad patient reach.

• Uptake is expected to be slow and steady, with a focus on both advanced therapy patients and those on high-dose steroids.

• Demonstrated steroid-sparing benefit is a key differentiator, generating excitement among physicians.

Competitive landscape and pipeline expansion

• Anticipates that competitor success (e.g., argenx in DM) will expand the market and benefit all players by increasing awareness and diagnosis.

• Brepocitinib is viewed as a platform for multiple rare disease indications, not just DM, with additional late-stage programs in development.